- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04492787
Efficacy and Safety of Changkang Granule in the Treatment of Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)
A Randomized,Double-blind,Placebo-controlled,Multicenter Study to Evaluate the Efficacy and Safety of Changkang Granule in the Treatment of Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The clinical phase of the study comprises up to 2 weeks of screening for patient's eligibility, a 2-week run-in period , a 8-week double-blind treatment period, and a 4-week safety follow-up.
Patients report their IBS-related symptoms daily from run-in until end of treatment.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Rui Liu
- Phone Number: 022-86343724
- Email: liurui@tasly.com
Study Locations
-
-
-
Beijing, China
- Not yet recruiting
- Xiyuan Hospital, China Academy of Traditional Chinese Medicine
-
Contact:
- Hua Zhen Li, director
- Phone Number: 13671157196
- Email: lixingka@aliyun.com
-
Dalian, China
- Not yet recruiting
- Shengjing Hospital of China Medical University
-
Contact:
- Ning Su Chen, director
- Phone Number: 18940251919
- Email: chensn@sj-hospital.org
-
Gansu, China
- Recruiting
- Gansu provincial hospital of TCM
-
Contact:
- Dong Xu Tian, director
- Phone Number: 15002591589
- Email: xytxd@163.com
-
Hunan, China
- Recruiting
- The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine
-
Contact:
- Bin Yu, director
- Phone Number: 13507314549
- Email: Yubin410@163.com
-
Shanghai, China
- Not yet recruiting
- Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
-
Contact:
- Biao Gong, director
- Phone Number: 18801800616
- Email: rachel_1983@126.com
-
Sichuan, China
- Not yet recruiting
- West China Hospital of Sichuan University
-
Contact:
- Hua Mei Wan, vice-director
- Phone Number: 13980082219
- Email: meihuawan@hotmail.com
-
Wenzhou, China
- Recruiting
- Wenzhou Hospital of Traditional Chinese Medicine
-
Contact:
- Ming Yao Zeng, director
- Phone Number: 13867704929
- Email: 250858111@qq.com
-
Xiamen, China
- Recruiting
- Xiamen Hospital of Traditional Chinese Medicine
-
Contact:
- Bin Yi Chen, director
- Phone Number: 18950126702
- Email: chenyb2004@163.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- The patients with diarrhea predominant irritable bowel syndrome (IBS-D) met Rome IV criteria;
- It is in accordance with the syndrome differentiation standard of TCM, such as the syndrome of liver Qi multiplying spleen, spleen stomach weakness, spleen kidney yang deficiency or large intestine damp heat syndrome;
- Male or female aged 18 to 65 years (including the boundary value);
- The weekly mean NRS score of abdominal pain was ≥ 3.0, and the number of days with stool type 6 or 7 was more than 2 days per week;
- IBS-SSS score>175;
- Signed informed consent voluntarily.
Exclusion Criteria:
- Patients with IBS-C、IBS-M or IBS-U;
- Those who had been diagnosed with organic diseases of digestive system, such as inflammatory bowel disease, intestinal tuberculosis, intestinal tumor, etc., or still combined with peptic ulcer and infectious diarrhea;
- Patients were diagnosed with similar symptoms of irritable bowel syndrome in the past, such as eosinophilic enteritis, collagen enteritis, lactose intolerance, etc;
- Patients with non intestinal diseases of digestive system, such as tuberculous peritonitis, gallstones, liver cirrhosis, chronic pancreatitis, etc;
- Previous diagnosis of systemic diseases affecting gastrointestinal function, such as hyperthyroidism or hypothyroidism, endometriosis, chronic renal insufficiency, autoimmune diseases, diabetes, etc
- With history of abdominal surgery (e.g., cholecystectomy);
- Patients with severe cardiovascular disease, liver, kidney and other major organ diseases, hematopoietic system diseases, tumor, nervous or mental system diseases (such as severe depression, severe anxiety)
- Those who could not stop using concomitant drugs (prokinetic agents, anticholinergics, calcium channel blockers, 5-HT3 receptor antagonists, antidiarrheal agents, antacids, antidepressants, antianxiety drugs, intestinal flora regulators, etc.) that affected gastrointestinal motility and function ;
- Taking emergency medication in the run-in period;
- Pregnant or lactating women;
- Those who are allergic to the test drug, emergency drug and its ingredients;
- Suspected or confirmed history of alcohol and drug abuse;
- Patients who participated in other clinical trials within one month before enrollment;
- The researchers believe that others are not suitable for clinical trials.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Changkang Granules
|
Take Changkang granule before meals twice a day , one bag for each time
|
PLACEBO_COMPARATOR: Changkang Placebo Granules
|
Take Changkang Placebo granule before meals twice a day , one bag for each time
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants Who Are Composite Responders Consistency Scores
Time Frame: 8 week
|
Composite responders are defined as participants who met the weekly response criteria for at least 50% of the weeks with diary entries over the 8-week interval. The patient will be considered a weekly responder if she/he meets both of the following criteria in the same week.
|
8 week
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants Who Are Responders in Abdominal Pain Scores
Time Frame: 8 week
|
Abdominal pain responders are defined as participants who met the weekly response criteria for at least 50% of the weeks with diary entries over the 8-week interval; Weekly response: decrease in weekly average of worst abdominal pain score in the past 24 hours of at least 30% compared with baseline.
|
8 week
|
Percentage of Participants Who Are Responders in Stool Consistency Scores
Time Frame: 8 week
|
Stool consistency responders are defined as participants who met the weekly response criteria for at least 50% of the weeks with diary entries over the 8-week interval. Weekly response: decrease of at least 50% in the number of days per week with at least one stool that has a consistency of Type 6 or 7 compared with baseline. |
8 week
|
Change from baseline to each week during follow up for IBS-symptoms abdominal pain;
Time Frame: 8 week
|
Abdominal Pain:Scored between 0 and 10 (none to severe).
|
8 week
|
Change from baseline to each week during follow up for IBS-symptoms stool consistency;
Time Frame: 8 week
|
Stool consistency:Bristol Stool Scale(Scored 1-7).
|
8 week
|
Change from baseline to each week during follow up for IBS-symptoms bloating
Time Frame: 8 week
|
Bloating:Scored between 0 and 10.
|
8 week
|
Change from baseline to each week during follow up for IBS-symptoms urgency
Time Frame: 8 week
|
The change of frequency of defecation urgency per week compared with baseline.
|
8 week
|
Change from baseline to each week during follow up for IBS-symptoms Defecation frequency
Time Frame: 8 week
|
Change from baseline in mean number of bowel movements per week.
|
8 week
|
Disappearance rate of traditional Chinese Medicine(TCM)symptom
Time Frame: 8 week
|
Each syndrome type has 2-3 symptoms,liver Qi multiplying spleen syndrome includes Chest and flank fullness, depression, irritability
|
8 week
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- TSL-TCM-CKKL-Ⅱ
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Irritable Bowel Syndrome With Diarrhea
-
ProgenaBiomeRecruitingIrritable Bowel Syndrome | Irritable Bowel Syndrome With Diarrhea | Irritable Bowel Syndrome With Constipation | Irritable Bowel Syndrome Characterized by Constipation | Irritable Bowel Syndrome Mixed | Irritable Bowel Syndrome Without Diarrhea | Irritable Bowel | Irritable Bowel Syndrome Aggravated and other conditionsUnited States
-
Federal Stare Budgetary Scientific Institution,...I.M. Sechenov First Moscow State Medical University; RML INVEST, Torkhovsky...CompletedIrritable Bowel Syndrome | Irritable Bowel Syndrome With Diarrhea | Irritable Bowel Syndrome With Constipation | Irritable Bowel Syndrome MixedRussian Federation
-
Istanbul Medipol University HospitalTepecik Training and Research Hospital; Bozyaka Training and Research Hospital and other collaboratorsRecruitingIrritable Bowel Syndrome | Irritable Bowel Syndrome With Diarrhea | Irritable Bowel Syndrome With Constipation | Irritable Bowel Syndrome MixedTurkey
-
University of California, Los AngelesCompletedIrritable Bowel Syndrome With Diarrhea | Irritable Bowel Syndrome With Mixed Bowel HabitsUnited States
-
Thomayer University HospitalCharles University, Czech RepublicActive, not recruitingIrritable Bowel Syndrome With Diarrhea | Irritable Bowel Syndrome MixedCzechia
-
CinPhloro Pharma, LLCRecruitingIrritable Bowel Syndrome With DiarrheaUnited States
-
Sahlgrenska University Hospital, SwedenBeneo-Institute; Atmo Biosciences Pty LtdRecruitingIrritable Bowel Syndrome With DiarrheaSweden
-
Bahria UniversityCompletedIrritable Bowel Syndrome With DiarrheaPakistan
-
Vedic Lifesciences Pvt. Ltd.CompletedIrritable Bowel Syndrome With DiarrheaIndia
-
I.M. Sechenov First Moscow State Medical UniversityActive, not recruitingIrritable Bowel Syndrome With DiarrheaRussian Federation
Clinical Trials on Changkang Granule
-
Henan University of Traditional Chinese MedicineUnknownPulmonary Disease, Chronic Obstructive
-
Korea Health Industry Development InstituteUnknown
-
Henan University of Traditional Chinese MedicineUnknown
-
Shanghai University of Traditional Chinese MedicineLonghua HospitalRecruiting
-
Xiyuan Hospital of China Academy of Chinese Medical...The First Affiliated Hospital of Henan University of Traditional Chinese... and other collaboratorsRecruitingNon-erosive Reflux Disease | Diarrhea-Predominant Irritable Bowel SyndromeChina
-
Xiyuan Hospital of China Academy of Chinese Medical...First Affiliated Hospital of Heilongjiang Chinese Medicine University; Liuzhou... and other collaboratorsRecruitingGastroesophageal Reflux | Functional DysphoniaChina
-
Heilongjiang Quanle Pharmaceutical Co., Ltd.Not yet recruiting
-
Peking University People's HospitalRecruitingAcute Exacerbation of Chronic Obstructive Pulmonary DiseaseChina
-
Dongzhimen Hospital, BeijingWuhan Third Hospital; The Second Affiliated Hospital of Tianjin University... and other collaboratorsUnknownCoronary Artery Disease | Diabetic Peripheral Neuropathy | Stroke, Ischemic | Angina Pectoris, StableChina
-
Xiyuan Hospital of China Academy of Chinese Medical...Guang'anmen Hospital of China Academy of Chinese Medical Sciences; China Academy...Recruiting